Apellis Pharmaceuticals Conference Call Announcement
WALTHAM, Mass. — Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) is gearing up to host a significant conference call and webcast aimed at discussing its financial outcomes for the fourth quarter and the entire year of 2024. This event is scheduled for a Friday morning and will commence at 8:30 a.m. ET.
How to Participate in the Call
To ensure seamless access to the live call, participants are encouraged to pre-register. This can easily be done prior to the scheduled time.
For those who prefer digital access, an audio webcast will also be available, along with a presentation deck. Interested parties can find this information on the “Events and Presentations” section of Apellis' investor relations page. After the call, a recording of the webcast will remain accessible for 90 days, enabling thorough review.
About Apellis Pharmaceuticals
Apellis Pharmaceuticals is recognized as a pioneering biopharmaceutical firm dedicated to the transformative development of therapies for relentless diseases. The company’s innovative approaches have led to the introduction of the first new class of complement medicines in over a decade, boasting two approved products that specifically target C3. This includes a groundbreaking therapy aimed at geographic atrophy, a paramount cause of global blindness. The company is enthusiastic about continuing to explore the potential of C3 targeting in treating various challenging diseases.
Company Commitment and Future Endeavors
With a robust foundation in scientific excellence, Apellis is devoted to making a tangible impact on patient lives through innovative treatments. The company firmly believes in the untapped opportunities provided by complement medicine, particularly in addressing serious conditions that have minimal treatment options. As Apellis navigates through its future, stakeholders remain optimistic about the advancements in their pipeline and the ongoing commitment to addressing unmet medical needs.
Connect with Apellis Pharmaceuticals
For those wishing to learn more about Apellis' groundbreaking therapies and ongoing research initiatives, further information can be explored on their official website or through their social media channels like Twitter and LinkedIn. Engaging with the company via these platforms offers insights into their vision, research endeavors, and community interaction.
Frequently Asked Questions
What is the purpose of the conference call?
The conference call aims to discuss Apellis Pharmaceuticals' financial results for the fourth quarter and full year of 2024.
How can I access the conference call?
Interested participants can pre-register for the call by visiting the appropriate link provided by Apellis. There will also be a live audio webcast available.
What are the key therapies developed by Apellis?
Apellis has developed two notable therapies targeting C3, including one that addresses geographic atrophy, which is a major cause of blindness.
How long will the webcast replay be available?
The replay of the conference call webcast will be accessible for 90 days after the event.
How can I learn more about Apellis Pharmaceuticals?
More information can be found on the Apellis website and through their social media platforms such as Twitter and LinkedIn.
